 Nuclear Medicine Market Insights, Competitive Landscape, and Market Forecast - 2033
The global Nuclear Medicine Market is entering a high-growth phase as healthcare systems increasingly adopt radiopharmaceuticals for early disease detection and targeted therapeutic intervention. T... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe global Nuclear Medicine Market is entering a high-growth phase as healthcare systems increasingly adopt radiopharmaceuticals for early disease detection and targeted therapeutic intervention. The market is valued at US$22.3 Bn in 2026 and is projected to reach US$46.2 Bn by 2033, expanding at a CAGR of 11.00% during the forecast period. Growth is supported by rising cancer and cardiovascular disease prevalence, wider use of PET and SPECT imaging, and rapid progress in theranostics.Market Insights Nuclear medicine uses small quantities of radioactive materials to diagnose and treat diseases at the molecular level. Unlike conventional imaging, which mainly shows anatomy, nuclear medicine highlights physiological activity, helping clinicians identify abnormalities earlier. This capability is strengthening its role in oncology, cardiology, neurology, thyroid disorders, and lymphoma management. Diagnostics continue to represent a major revenue contributor, led by Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET). PET imaging is gaining strong traction in oncology because it supports staging, recurrence monitoring, and treatment response assessment. SPECT remains widely used in cardiac imaging and bone scans due to established workflows. At the same time, therapeutic nuclear medicine is advancing through alpha emitters, beta emitters, and brachytherapy, creating opportunities for targeted disease control. Drivers The rising global burden of cancer is a major factor shaping market expansion. Nuclear medicine enables clinicians to detect tumors, evaluate metastasis, and select patients for targeted radioligand therapies. Growing adoption of prostate cancer imaging agents, neuroendocrine tumor therapies, and lymphoma-related applications is reinforcing demand for specialized radiopharmaceuticals. Cardiovascular disease prevalence is another key driver. Myocardial perfusion imaging using SPECT remains an essential tool for assessing coronary artery disease, risk stratification, and treatment planning. Neurological applications are also increasing as PET and SPECT help evaluate dementia, Parkinsonian syndromes, epilepsy, and other brain disorders. Technology improvements support adoption. Hybrid imaging systems, improved cyclotron and generator infrastructure, automated radiopharmacy solutions, and better isotope production networks are helping healthcare providers improve scan quality, workflow efficiency, and patient access. Regulatory support for innovative radiopharmaceuticals and increasing investment in nuclear medicine facilities are strengthening momentum. Business Opportunity The market offers strong opportunities for radiopharmaceutical developers, imaging technology providers, isotope suppliers, contract manufacturing organizations, hospitals, and diagnostic networks. Companies that can ensure reliable isotope supply, high-quality manufacturing, and compliant distribution will be well positioned as demand rises across developed and emerging markets. Theranostics represents a major business opportunity. By pairing diagnostic imaging agents with therapeutic radiopharmaceuticals, healthcare providers can identify suitable patients, monitor treatment response, and reduce unnecessary interventions. This approach is gaining commercial importance in oncology. There is also significant opportunity in expanding PET access beyond major metropolitan hospitals. Diagnostic centres and regional hospitals are investing in nuclear medicine capabilities to serve growing patient volumes. Partnerships between pharmaceutical companies, imaging centres, academic institutions, and healthcare providers will be critical for accelerating clinical adoption and improving availability. Region Analysis North America is expected to remain a leading market, supported by advanced healthcare infrastructure, strong reimbursement systems, high cancer screening activity, and the presence of major radiopharmaceutical companies. The United States continues to see strong demand for PET and SPECT procedures, particularly in oncology and cardiology. Europe is also a significant market, driven by established nuclear medicine practices, research collaborations, and growing adoption of targeted therapies. Countries with strong hospital networks and radiopharmacy capabilities are expected to contribute steadily to market growth. Asia Pacific is projected to record rapid expansion due to increasing healthcare spending, rising cancer incidence, improving diagnostic infrastructure, and growing awareness of advanced imaging. China, India, Japan, South Korea, and Australia are expected to offer notable growth opportunities as hospitals and diagnostic centres invest in PET, SPECT, and radiopharmaceutical services. Latin America and the Middle East & Africa are emerging markets where growth is supported by improving healthcare access, public and private investment, and increasing demand for advanced diagnostic solutions. However, isotope availability, skilled workforce shortages, and infrastructure gaps remain key challenges. Key Players Leading companies in the Nuclear Medicine Market are focusing on product development, strategic partnerships, isotope supply expansion, and regulatory approvals to strengthen their market position. Key players include: • Advanced Accelerator Applications • Norgine B.V. • Blue Earth Diagnostics Ltd. • Curium Pharma • Digirad Corporation • Jubilant Radiopharma • Karyopharm • Lantheus Holdings, Inc. • Northstar Nuclear Medicine • Precirix NV • Sinotau Pharmaceuticals • Solcom • Zionexa • Cardinal Health • Bracco Diagnostic Inc. Market Segmentation By Product Type: • Diagnostics o Single Photon Emission Computed Tomography (SPECT) o Positron Emission Tomography (PET) • Therapeutics o Alpha Emitters o Beta Emitters o Brachytherapy By Application: • Cardiology • Neurology • Oncology • Thyroid • Lymphoma • Other Application By End User: • Hospitals & Clinics • Diagnostic Centres • Others By Geographic Coverage: • North America • Europe • Asia Pacific • Latin America • Middle East & Africa Table of Contents1. Executive Summary1.1. Global Nuclear Medicine Market Snapshot 1.2. Future Projections 1.3. Key Market Trends 1.4. Regional Snapshot, by Value, 2026 1.5. Analyst Recommendations 2. Market Overview 2.1. Market Definitions and Segmentations 2.2. Market Dynamics 2.2.1. Drivers 2.2.2. Restraints 2.2.3. Market Opportunities 2.3. Value Chain Analysis 2.4. COVID-19 Impact Analysis 2.5. Porter's Five Forces Analysis 2.6. Impact of Russia-Ukraine Conflict 2.7. PESTLE Analysis 2.8. Regulatory Analysis 2.9. Price Trend Analysis 2.9.1. Current Prices and Future Projections, 2025-2033 2.9.2. Price Impact Factors 3. Global Nuclear Medicine Market Outlook, 2020 - 2033 3.1. Global Nuclear Medicine Market Outlook, by Product Type, Value (US$ Bn), 2020-2033 3.1.1. Diagnostics 3.1.1.1. Single Photon Emission Computed Tomography (SPECT) 3.1.1.2. Positron Emission Tomography (PET) 3.1.2. Therapeutics 3.1.2.1. Alpha Emitters 3.1.2.2. Beta Emitters 3.1.2.3. Brachytherapy 3.2. Global Nuclear Medicine Market Outlook, by Application, Value (US$ Bn), 2020-2033 3.2.1. Cardiology 3.2.2. Neurology 3.2.3. Oncology 3.2.4. Thyroid 3.2.5. Lymphoma 3.2.6. Other Application 3.3. Global Nuclear Medicine Market Outlook, by End User, Value (US$ Bn), 2020-2033 3.3.1. Hospitals & Clinics 3.3.2. Diagnostic Centres 3.3.3. Others 3.4. Global Nuclear Medicine Market Outlook, by Region, Value (US$ Bn), 2020-2033 3.4.1. North America 3.4.2. Europe 3.4.3. Asia Pacific 3.4.4. Latin America 3.4.5. Middle East & Africa 4. North America Nuclear Medicine Market Outlook, 2020 - 2033 4.1. North America Nuclear Medicine Market Outlook, by Product Type, Value (US$ Bn), 2020-2033 4.1.1. Diagnostics 4.1.1.1. Single Photon Emission Computed Tomography (SPECT) 4.1.1.2. Positron Emission Tomography (PET) 4.1.2. Therapeutics 4.1.2.1. Alpha Emitters 4.1.2.2. Beta Emitters 4.1.2.3. Brachytherapy 4.2. North America Nuclear Medicine Market Outlook, by Application, Value (US$ Bn), 2020-2033 4.2.1. Cardiology 4.2.2. Neurology 4.2.3. Oncology 4.2.4. Thyroid 4.2.5. Lymphoma 4.2.6. Other Application 4.3. North America Nuclear Medicine Market Outlook, by End User, Value (US$ Bn), 2020-2033 4.3.1. Hospitals & Clinics 4.3.2. Diagnostic Centres 4.3.3. Others 4.4. North America Nuclear Medicine Market Outlook, by Country, Value (US$ Bn), 2020-2033 4.4.1. U.S. Nuclear Medicine Market Outlook, by Product Type, 2020-2033 4.4.2. U.S. Nuclear Medicine Market Outlook, by Application, 2020-2033 4.4.3. U.S. Nuclear Medicine Market Outlook, by End User, 2020-2033 4.4.4. Canada Nuclear Medicine Market Outlook, by Product Type, 2020-2033 4.4.5. Canada Nuclear Medicine Market Outlook, by Application, 2020-2033 4.4.6. Canada Nuclear Medicine Market Outlook, by End User, 2020-2033 4.5. BPS Analysis/Market Attractiveness Analysis 5. Europe Nuclear Medicine Market Outlook, 2020 - 2033 5.1. Europe Nuclear Medicine Market Outlook, by Product Type, Value (US$ Bn), 2020-2033 5.1.1. Diagnostics 5.1.1.1. Single Photon Emission Computed Tomography (SPECT) 5.1.1.2. Positron Emission Tomography (PET) 5.1.2. Therapeutics 5.1.2.1. Alpha Emitters 5.1.2.2. Beta Emitters 5.1.2.3. Brachytherapy 5.2. Europe Nuclear Medicine Market Outlook, by Application, Value (US$ Bn), 2020-2033 5.2.1. Cardiology 5.2.2. Neurology 5.2.3. Oncology 5.2.4. Thyroid 5.2.5. Lymphoma 5.2.6. Other Application 5.3. Europe Nuclear Medicine Market Outlook, by End User, Value (US$ Bn), 2020-2033 5.3.1. Hospitals & Clinics 5.3.2. Diagnostic Centres 5.3.3. Others 5.4. Europe Nuclear Medicine Market Outlook, by Country, Value (US$ Bn), 2020-2033 5.4.1. Germany Nuclear Medicine Market Outlook, by Product Type, 2020-2033 5.4.2. Germany Nuclear Medicine Market Outlook, by Application, 2020-2033 5.4.3. Germany Nuclear Medicine Market Outlook, by End User, 2020-2033 5.4.4. Italy Nuclear Medicine Market Outlook, by Product Type, 2020-2033 5.4.5. Italy Nuclear Medicine Market Outlook, by Application, 2020-2033 5.4.6. Italy Nuclear Medicine Market Outlook, by End User, 2020-2033 5.4.7. France Nuclear Medicine Market Outlook, by Product Type, 2020-2033 5.4.8. France Nuclear Medicine Market Outlook, by Application, 2020-2033 5.4.9. France Nuclear Medicine Market Outlook, by End User, 2020-2033 5.4.10. U.K. Nuclear Medicine Market Outlook, by Product Type, 2020-2033 5.4.11. U.K. Nuclear Medicine Market Outlook, by Application, 2020-2033 5.4.12. U.K. Nuclear Medicine Market Outlook, by End User, 2020-2033 5.4.13. Spain Nuclear Medicine Market Outlook, by Product Type, 2020-2033 5.4.14. Spain Nuclear Medicine Market Outlook, by Application, 2020-2033 5.4.15. Spain Nuclear Medicine Market Outlook, by End User, 2020-2033 5.4.16. Russia Nuclear Medicine Market Outlook, by Product Type, 2020-2033 5.4.17. Russia Nuclear Medicine Market Outlook, by Application, 2020-2033 5.4.18. Russia Nuclear Medicine Market Outlook, by End User, 2020-2033 5.4.19. Rest of Europe Nuclear Medicine Market Outlook, by Product Type, 2020-2033 5.4.20. Rest of Europe Nuclear Medicine Market Outlook, by Application, 2020-2033 5.4.21. Rest of Europe Nuclear Medicine Market Outlook, by End User, 2020-2033 5.5. BPS Analysis/Market Attractiveness Analysis 6. Asia Pacific Nuclear Medicine Market Outlook, 2020 - 2033 6.1. Asia Pacific Nuclear Medicine Market Outlook, by Product Type, Value (US$ Bn), 2020-2033 6.1.1. Diagnostics 6.1.1.1. Single Photon Emission Computed Tomography (SPECT) 6.1.1.2. Positron Emission Tomography (PET) 6.1.2. Therapeutics 6.1.2.1. Alpha Emitters 6.1.2.2. Beta Emitters 6.1.2.3. Brachytherapy 6.2. Asia Pacific Nuclear Medicine Market Outlook, by Application, Value (US$ Bn), 2020-2033 6.2.1. Cardiology 6.2.2. Neurology 6.2.3. Oncology 6.2.4. Thyroid 6.2.5. Lymphoma 6.2.6. Other Application 6.3. Asia Pacific Nuclear Medicine Market Outlook, by End User, Value (US$ Bn), 2020-2033 6.3.1. Hospitals & Clinics 6.3.2. Diagnostic Centres 6.3.3. Others 6.4. Asia Pacific Nuclear Medicine Market Outlook, by Country, Value (US$ Bn), 2020-2033 6.4.1. China Nuclear Medicine Market Outlook, by Product Type, 2020-2033 6.4.2. China Nuclear Medicine Market Outlook, by Application, 2020-2033 6.4.3. China Nuclear Medicine Market Outlook, by End User, 2020-2033 6.4.4. Japan Nuclear Medicine Market Outlook, by Product Type, 2020-2033 6.4.5. Japan Nuclear Medicine Market Outlook, by Application, 2020-2033 6.4.6. Japan Nuclear Medicine Market Outlook, by End User, 2020-2033 6.4.7. South Korea Nuclear Medicine Market Outlook, by Product Type, 2020-2033 6.4.8. South Korea Nuclear Medicine Market Outlook, by Application, 2020-2033 6.4.9. South Korea Nuclear Medicine Market Outlook, by End User, 2020-2033 6.4.10. India Nuclear Medicine Market Outlook, by Product Type, 2020-2033 6.4.11. India Nuclear Medicine Market Outlook, by Application, 2020-2033 6.4.12. India Nuclear Medicine Market Outlook, by End User, 2020-2033 6.4.13. Southeast Asia Nuclear Medicine Market Outlook, by Product Type, 2020-2033 6.4.14. Southeast Asia Nuclear Medicine Market Outlook, by Application, 2020-2033 6.4.15. Southeast Asia Nuclear Medicine Market Outlook, by End User, 2020-2033 6.4.16. Rest of SAO Nuclear Medicine Market Outlook, by Product Type, 2020-2033 6.4.17. Rest of SAO Nuclear Medicine Market Outlook, by Application, 2020-2033 6.4.18. Rest of SAO Nuclear Medicine Market Outlook, by End User, 2020-2033 6.5. BPS Analysis/Market Attractiveness Analysis 7. Latin America Nuclear Medicine Market Outlook, 2020 - 2033 7.1. Latin America Nuclear Medicine Market Outlook, by Product Type, Value (US$ Bn), 2020-2033 7.1.1. Diagnostics 7.1.1.1. Single Photon Emission Computed Tomography (SPECT) 7.1.1.2. Positron Emission Tomography (PET) 7.1.2. Therapeutics 7.1.2.1. Alpha Emitters 7.1.2.2. Beta Emitters 7.1.2.3. Brachytherapy 7.2. Latin America Nuclear Medicine Market Outlook, by Application, Value (US$ Bn), 2020-2033 7.2.1. Cardiology 7.2.2. Neurology 7.2.3. Oncology 7.2.4. Thyroid 7.2.5. Lymphoma 7.2.6. Other Application 7.3. Latin America Nuclear Medicine Market Outlook, by End User, Value (US$ Bn), 2020-2033 7.3.1. Hospitals & Clinics 7.3.2. Diagnostic Centres 7.3.3. Others 7.4. Latin America Nuclear Medicine Market Outlook, by Country, Value (US$ Bn), 2020-2033 7.4.1. Brazil Nuclear Medicine Market Outlook, by Product Type, 2020-2033 7.4.2. Brazil Nuclear Medicine Market Outlook, by Application, 2020-2033 7.4.3. Brazil Nuclear Medicine Market Outlook, by End User, 2020-2033 7.4.4. Mexico Nuclear Medicine Market Outlook, by Product Type, 2020-2033 7.4.5. Mexico Nuclear Medicine Market Outlook, by Application, 2020-2033 7.4.6. Mexico Nuclear Medicine Market Outlook, by End User, 2020-2033 7.4.7. Argentina Nuclear Medicine Market Outlook, by Product Type, 2020-2033 7.4.8. Argentina Nuclear Medicine Market Outlook, by Application, 2020-2033 7.4.9. Argentina Nuclear Medicine Market Outlook, by End User, 2020-2033 7.4.10. Rest of LATAM Nuclear Medicine Market Outlook, by Product Type, 2020-2033 7.4.11. Rest of LATAM Nuclear Medicine Market Outlook, by Application, 2020-2033 7.4.12. Rest of LATAM Nuclear Medicine Market Outlook, by End User, 2020-2033 7.5. BPS Analysis/Market Attractiveness Analysis 8. Middle East & Africa Nuclear Medicine Market Outlook, 2020 - 2033 8.1. Middle East & Africa Nuclear Medicine Market Outlook, by Product Type, Value (US$ Bn), 2020-2033 8.1.1. Diagnostics 8.1.1.1. Single Photon Emission Computed Tomography (SPECT) 8.1.1.2. Positron Emission Tomography (PET) 8.1.2. Therapeutics 8.1.2.1. Alpha Emitters 8.1.2.2. Beta Emitters 8.1.2.3. Brachytherapy 8.2. Middle East & Africa Nuclear Medicine Market Outlook, by Application, Value (US$ Bn), 2020-2033 8.2.1. Cardiology 8.2.2. Neurology 8.2.3. Oncology 8.2.4. Thyroid 8.2.5. Lymphoma 8.2.6. Other Application 8.3. Middle East & Africa Nuclear Medicine Market Outlook, by End User, Value (US$ Bn), 2020-2033 8.3.1. Hospitals & Clinics 8.3.2. Diagnostic Centres 8.3.3. Others 8.4. Middle East & Africa Nuclear Medicine Market Outlook, by Country, Value (US$ Bn), 2020-2033 8.4.1. GCC Nuclear Medicine Market Outlook, by Product Type, 2020-2033 8.4.2. GCC Nuclear Medicine Market Outlook, by Application, 2020-2033 8.4.3. GCC Nuclear Medicine Market Outlook, by End User, 2020-2033 8.4.4. South Africa Nuclear Medicine Market Outlook, by Product Type, 2020-2033 8.4.5. South Africa Nuclear Medicine Market Outlook, by Application, 2020-2033 8.4.6. South Africa Nuclear Medicine Market Outlook, by End User, 2020-2033 8.4.7. Egypt Nuclear Medicine Market Outlook, by Product Type, 2020-2033 8.4.8. Egypt Nuclear Medicine Market Outlook, by Application, 2020-2033 8.4.9. Egypt Nuclear Medicine Market Outlook, by End User, 2020-2033 8.4.10. Nigeria Nuclear Medicine Market Outlook, by Product Type, 2020-2033 8.4.11. Nigeria Nuclear Medicine Market Outlook, by Application, 2020-2033 8.4.12. Nigeria Nuclear Medicine Market Outlook, by End User, 2020-2033 8.4.13. Rest of Middle East Nuclear Medicine Market Outlook, by Product Type, 2020-2033 8.4.14. Rest of Middle East Nuclear Medicine Market Outlook, by Application, 2020-2033 8.4.15. Rest of Middle East Nuclear Medicine Market Outlook, by End User, 2020-2033 8.5. BPS Analysis/Market Attractiveness Analysis 9. Competitive Landscape 9.1. Company Vs Segment Heatmap 9.2. Company Market Share Analysis, 2025 9.3. Competitive Dashboard 9.4. Company Profiles 9.4.1. Advanced Accelerator Applications 9.4.1.1. Company Overview 9.4.1.2. Product Portfolio 9.4.1.3. Financial Overview 9.4.1.4. Business Strategies and Developments 9.4.2. Norgine B.V. 9.4.3. Blue Earth Diagnostics Ltd. 9.4.4. Curium Pharma 9.4.5. Digirad Corporation 9.4.6. Jubilant Radiopharma 9.4.7. Karyopharm 9.4.8. Lantheus Holdings, Inc. 9.4.9. Northstar Nuclear Medicine 9.4.10. Precirix NV 10. Appendix 10.1. Research Methodology 10.2. Report Assumptions 10.3. Acronyms and Abbreviations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医薬）の最新刊レポート
Fairfield Market Research社の 医薬品・バイオテクノロジー分野 での最新刊レポート
本レポートと同じKEY WORD（nuclear）の最新刊レポート
よくあるご質問Fairfield Market Research社はどのような調査会社ですか?Fairfield Market Researchでは、最新かつ最も関連性の高い市場データと洞察に満ちた詳細なレポートを発行しています。広範囲にわたり、業界動向や市場ベースのデータを含んでおり、顧客が... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
